Soleno Therapeutics Acquired by Neurocrine, Shares Surge 32%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy SLNO?
Source: Fool
- Acquisition Agreement: Soleno Therapeutics has signed a $2.9 billion acquisition deal with Neurocrine Biosciences, where Neurocrine will pay $53 per share in cash, with the transaction expected to close within 90 days, indicating strong acquisition interest in Soleno.
- Stock Surge: Following the acquisition announcement, Soleno's shares surged 32% during the trading session, reaching $52.25 per share, reflecting positive market sentiment and investor confidence in the deal.
- FDA Approval Context: Soleno's Vykat XR, approved by the FDA in March 2025 as the only treatment for hyperphagia associated with Prader-Willi Syndrome, enhances its market position in rare diseases, attracting Neurocrine's acquisition interest.
- Strategic Implications: Neurocrine's CEO stated that the acquisition will advance the company's revenue growth and portfolio diversification strategy, highlighting its expansion strategy in the biotech sector and further solidifying its market leadership.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.780
Low
75.00
Averages
110.50
High
125.00
Current: 52.780
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action Lawsuit Against Soleno Therapeutics
- Lawsuit Background: Soleno Therapeutics is facing a class action lawsuit due to safety concerns regarding its DCCR drug, with investors who purchased stock between March 26, 2025, and November 4, 2026, potentially eligible to recover losses.
- Stock Price Volatility: On August 15, 2025, Soleno's stock price dropped 11.98% to $68.09 within two days following a report from Scorpion Capital, indicating market concerns over the drug's safety.
- Further Losses: On September 10, 2025, Soleno disclosed a patient death linked to DCCR, causing the stock to decline by 19.21% to $56.72, exacerbating investor losses.
- Financial Impact: On November 4, 2025, Soleno reported that DCCR's market launch was negatively affected, leading to a 26.59% drop in stock price to $46.87, reflecting a severe loss of investor confidence in the company's future prospects.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Merger Investigations: Monteverde Law Firm is investigating the merger between Wintergreen Acquisition Corp. and KIKA Technology Inc., where KIKA shareholders will receive ordinary shares based on valuation, highlighting the firm's commitment to shareholder rights.
- Cash Acquisition Assurance: Centessa Pharmaceuticals shareholders are expected to receive $38 per share in cash along with a contingent value right worth up to $9, indicating the company's dedication to shareholder compensation and potential future gains.
- Shareholder Voting Schedule: Stellar Bancorp shareholders will vote on May 27, 2026, with expectations of receiving 0.3803 shares of Prosperity common stock and $11.36 in cash per share, reflecting the importance of transparency and shareholder engagement in merger transactions.
- Tender Offer Deadline: Soleno Therapeutics shareholders are expected to receive $53 per share in cash, with the tender offer expiring on May 15, 2026, emphasizing the urgency for shareholders to act to secure their interests.
See More
Soleno Therapeutics Faces Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ: SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26, 2025, and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), including potential heart failure in children, leading to substantial investor losses.
- Misleading Market Performance: While Soleno claimed that the DCCR launch
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Lawsuit Background: DJS Law Group alerts investors about a class action lawsuit against Soleno Therapeutics for violations of securities laws, concerning stock purchases from March 26, 2025, to November 4, 2025, with a deadline for participation set for May 5, 2026.
- False Statement Allegations: The complaint alleges that Soleno downplayed safety concerns during its Phase 3 clinical trial of DCCR, leading to accusations that its public statements were false and misleading, which could have misled investors.
- Declining Commercial Viability: The commercial viability of DCCR is now in question, as Soleno failed to disclose associated risks in a timely manner, potentially resulting in significant losses for investors following a drop in stock price, raising further concerns about the company's future.
- Legal Service Advantage: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through aggressive legal advocacy, which has attracted attention from major hedge funds and alternative asset managers.
See More
Soleno Therapeutics Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, or risk losing the opportunity to represent other investors in the class action.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug during clinical trials, including significant issues like fluid retention in participants, leading to investor losses when the true risks were revealed, highlighting the company's inadequate risk management prior to commercialization.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, while also achieving the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in securities class actions to ensure optimal representation during litigation and avoid firms that merely act as intermediaries.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater safety risks and potential legal repercussions post-commercialization.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and extensive experience in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries without litigation experience.
See More
Reminder of Class Action Lawsuit Against Soleno Therapeutics
- Lawsuit Background: Soleno Therapeutics is facing a class action lawsuit due to safety concerns regarding its DCCR drug, with investors who purchased stock between March 26, 2025, and November 4, 2026, potentially eligible to recover losses.
- Stock Price Volatility: On August 15, 2025, Soleno's stock price dropped 11.98% to $68.09 within two days following a report from Scorpion Capital, indicating market concerns over the drug's safety.
- Further Losses: On September 10, 2025, Soleno disclosed a patient death linked to DCCR, causing the stock to decline by 19.21% to $56.72, exacerbating investor losses.
- Financial Impact: On November 4, 2025, Soleno reported that DCCR's market launch was negatively affected, leading to a 26.59% drop in stock price to $46.87, reflecting a severe loss of investor confidence in the company's future prospects.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Merger Investigations: Monteverde Law Firm is investigating the merger between Wintergreen Acquisition Corp. and KIKA Technology Inc., where KIKA shareholders will receive ordinary shares based on valuation, highlighting the firm's commitment to shareholder rights.
- Cash Acquisition Assurance: Centessa Pharmaceuticals shareholders are expected to receive $38 per share in cash along with a contingent value right worth up to $9, indicating the company's dedication to shareholder compensation and potential future gains.
- Shareholder Voting Schedule: Stellar Bancorp shareholders will vote on May 27, 2026, with expectations of receiving 0.3803 shares of Prosperity common stock and $11.36 in cash per share, reflecting the importance of transparency and shareholder engagement in merger transactions.
- Tender Offer Deadline: Soleno Therapeutics shareholders are expected to receive $53 per share in cash, with the tender offer expiring on May 15, 2026, emphasizing the urgency for shareholders to act to secure their interests.
See More
Soleno Therapeutics Faces Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ: SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26, 2025, and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), including potential heart failure in children, leading to substantial investor losses.
- Misleading Market Performance: While Soleno claimed that the DCCR launch
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Lawsuit Background: DJS Law Group alerts investors about a class action lawsuit against Soleno Therapeutics for violations of securities laws, concerning stock purchases from March 26, 2025, to November 4, 2025, with a deadline for participation set for May 5, 2026.
- False Statement Allegations: The complaint alleges that Soleno downplayed safety concerns during its Phase 3 clinical trial of DCCR, leading to accusations that its public statements were false and misleading, which could have misled investors.
- Declining Commercial Viability: The commercial viability of DCCR is now in question, as Soleno failed to disclose associated risks in a timely manner, potentially resulting in significant losses for investors following a drop in stock price, raising further concerns about the company's future.
- Legal Service Advantage: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through aggressive legal advocacy, which has attracted attention from major hedge funds and alternative asset managers.
See More
Soleno Therapeutics Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, or risk losing the opportunity to represent other investors in the class action.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug during clinical trials, including significant issues like fluid retention in participants, leading to investor losses when the true risks were revealed, highlighting the company's inadequate risk management prior to commercialization.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, while also achieving the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in securities class actions to ensure optimal representation during litigation and avoid firms that merely act as intermediaries.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater safety risks and potential legal repercussions post-commercialization.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and extensive experience in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries without litigation experience.
See More
